The DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics
Abstract
Understanding inter-subject variability in drug pharmacokinetics and pharmacodynamics is important to ensure that all patients attain suitable drug exposure to achieve efficacy and avoid toxicity. Inter-subject variability in the pharmacokinetics of therapeutic monoclonal antibodies (mAbs) is generally moderate to high; however, the factors responsible for the high inter-subject variability have not been comprehensively reviewed. In this review, the extent of inter-subject variability for mAb pharmacokinetics is presented and potential factors contributing to this variability are explored and summarised. Disease status, age, sex, ethnicity, body size, genetic polymorphisms, concomitant medication, co-morbidities, immune status and multiple other patient-specific details have been considered. The inter-subject variability for mAb pharmacokinetics most likely depends on the complex interplay of multiple factors. However, studies aimed at investigating the reasons for the inter-subject variability are sparse. Population pharmacokinetic models and physiologically based pharmacokinetic models are useful tools to identify important covariates, aiding in the understanding of factors contributing to inter-subject variability. Further understanding of inter-subject variability in pharmacokinetics should aid in development of dosing regimens that are more appropriate.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many other factors, such as antibody properties (hydrophobicity, charge,38 glycosylation patterns39), intersubject variability (disease status, body size, genetic polymorphisms, concomitant medication, comorbidities, etc.40), and immune‐mediated response generated by mAbs administration can also impact mAb clearance.”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [40]
In the citing paper
“Once in clinical development, clinical pharmacology studies can identify the covariates and potential sources of intersubject variability; establish exposure–response relationships in patients, and aid in development of a dosing regimen.40”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [40]
Citations
Cites
Baselga, J. M., Tripathy, D., Mendelsohn, J. M., Baughman, S. A., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J. L., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,382
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Body composition of reference children from birth to age 10 years
Fomon, S. J., Haschke, F., Ziegler, E., & Nelson, S. (1982) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/35.5.1169 · Cited by 1,264
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D. L., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,066
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Baselga, J. M., Pfister, D. G., Cooper, M. R., Cohen, R. B., Burtness, B. A., Bos, M. M. E. M., D’Andrea, G. M., Seidman, A. D., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
The physiology of the lymphatic system
Swartz, M. A. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00150-8 · Cited by 738
Waldmann, T. A., & Strober, W. (2015) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000385919 · Cited by 731
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Transport of Molecules, Particles, and Cells in Solid Tumors
Jain, R. K. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.241 · Cited by 701
Research works printed but not linked: 3
- Lentner C. Geigy scientific tables, vol. 1: units of measurement, body fluids, composition of the body, and nutrition. 8th ed. Basel: Wiley; 1981. pp. 217–27.
- Kauffman R. Drug therapeutics in the infant and child. In: Yaffe S, Aranda J, editors. Pediatric pharmacology: therapeutic principles in practise. Philadelphia: WB Saunders; 1992. p. 212–9.
- Freeman T. Gamma globulin metabolism in normal humans and in patients. Ser Haematol. 1965;4:76–86.
Cited by
Sorted by citations
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30173-9 · Cited by 939
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
Immunogenicity of TNF-Inhibitors
Atiqi, S., Hooijberg, F., Loeff, F. C., Rispens, T., & Wolbink, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00312 · Cited by 182
Paper‐Based Antibody Detection Devices Using Bioluminescent BRET‐Switching Sensor Proteins
Tenda, K., van Gerven, B., Arts, R., Hiruta, Y., Merkx, M., & Citterio, D. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201808070 · Cited by 151
Johnson, K. W., Morin, S. M., Wroblewski, V. J., & Johnson, M. P. (2019) · Cephalalgia · doi:10.1177/0333102419844711 · Cited by 107
Immunogenicity of biologic agents in rheumatology
Strand, V., Gonçalves, J., & Isaacs, J. D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00540-8 · Cited by 103
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition
Thomas, V. A., & Balthasar, J. P. (2019) · Antibodies · doi:10.3390/antib8040056 · Cited by 106
Age and sex in drug development and testing for adults
Tannenbaum, C., & Day, D. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.027 · Cited by 87
Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology
Bajaj, G., Suryawanshi, S., Roy, A., & Gupta, M. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13996 · Cited by 68
Varkhede, N. R., & Forrest, L. M. (2018) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30028 · Cited by 67
Tumor necrosis factor inhibitors in psoriatic arthritis
Mantravadi, S., Ogdie, A., & Kraft, W. K. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1329009 · Cited by 59
Dual-Color Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor Antibodies
van Rosmalen, M., Ni, Y., Vervoort, D. F. M., Arts, R., Ludwig, S. K. J., & Merkx, M. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b00041 · Cited by 52
Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review
Donners, A. A. M. T., Rademaker, C. M. A., Bevers, L. A. H., Huitema, A. D. R., Schutgens, R. E. G., Egberts, T. C. G., & Fischer, K. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01042-w · Cited by 48
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans
Ternant, D., Azzopardi, N., Raoul, W., Bejan‐Angoulvant, T., & Paintaud, G. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0680-3 · Cited by 45
Huang, S., Tang, R., Zhang, T., Zhao, J. T., Jiang, Z., & Wang, Q. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112678 · Cited by 43
Optimal Physicochemical Properties of Antibody–Nanoparticle Conjugates for Improved Tumor Targeting
Mittelheisser, V., Coliat, P., Moeglin, É., Goepp, L., Goetz, J. G., Charbonnière, L. J., Pivot, X. B., & Detappe, A. (2022) · Advanced Materials · doi:10.1002/adma.202110305 · Cited by 48
Hayato, S., Takenaka, O., Reddy, S. H. S., Landry, I. S., Reyderman, L., Koyama, A., Swanson, C. J., Yasuda, S., & Hussein, Z. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12862 · Cited by 41
Gehin, J. E., Goll, G. L., Brun, M. K., Jani, M., Bolstad, N., & Syversen, S. W. (2022) · BioDrugs · doi:10.1007/s40259-022-00559-1 · Cited by 41
Brun, M. K., Goll, G. L., Jørgensen, K. K., Sexton, J., Gehin, J. E., Sandanger, Ø., Olsen, I. C., Klaasen, R. A., Warren, D. J., Mørk, C., et al. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13495 · Cited by 40
Considerations for dosing immunoglobulin in obese patients
Hodkinson, J. P. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.12955 · Cited by 38
Tang, Y., & Cao, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030422 · Cited by 42
Ruperto, N., Brunner, H. I., Pacheco‐Tena, C., Louw, I., Vega‐Cornejo, G., Spindler, A. J., Kingsbury, D. J., Schmeling, H., Borzutzky, A., Cuttica, R. J., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab021 · Cited by 34
Malik, P. R. V., Hamadeh, A., Phipps, C. J., & Edginton, A. N. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9515-3 · Cited by 30
Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses
Canzian, J., Conforti, F., Jacobs, F., Benvenuti, C., Gaudio, M., Gerosa, R., Sanctis, R. D., & Zambelli, A. (2025) · Cancers · doi:10.3390/cancers17071054 · Cited by 32
Fiedler‐Kelly, J., Cohen‐Barak, O., Morris, D., Ludwig, E. A., Rasamoelisolo, M., Shen, H., & Levi, M. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14096 · Cited by 29
Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars
Niazi, S. K. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s378813 · Cited by 28
Chua, L., Friedrich, S. W., & Zhang, X. C. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01281-z · Cited by 29
Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile
Germain, M., Meyre, M.-E., Poul, L., Paolini, M. S., Berjaud, C., Mpambani, F., Bergère, M., Lévy, L., & Pottier, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-23140-9 · Cited by 26
Shimizu, R., Sonoyama, T., Fukuhara, T., Kuwata, A., Matsuo, Y., & Kubota, R. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01309-z · Cited by 24
Opportunities and Challenges for PBPK Model of mAbs in Paediatrics and Pregnancy
Gill, K. L., & Jones, H. M. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00722-0 · Cited by 24
Self-citationMaas, B. M., & Cao, Y. (2018) · mAbs · doi:10.1080/19420862.2018.1506648 · Cited by 23
Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?
Bastida, C., Ruíz-Esquide, V., Pascal, M., Yagüe, J., Sanmartí, R., & Soy, D. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13192 · Cited by 23
Shang, J., Huang, L., Huang, J., Ren, X., Liu, Y., & Feng, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871372 · Cited by 22
Majid, O., Cao, Y., Willis, B. A., Hayato, S., Takenaka, O., Lalovic, B. B., Reddy, S. H. S., Penner, N., Reyderman, L., Yasuda, S., et al. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13224 · Cited by 21
Leu, J. H., Shiff, N. J., Clark, M., Bensley, K., Lomax, K. G., Berezny, K., Nelson, R. M., Zhou, H., & Xu, Z. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00533-y · Cited by 21
Fokkink, W. R., Koch, B., Ramakers, C. R. B., van Doorn, P. A., van Gelder, T., & Jacobs, B. C. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.693 · Cited by 21
Paper‐Based Antibody Detection Devices Using Bioluminescent BRET‐Switching Sensor Proteins
Tenda, K., van Gerven, B., Arts, R., Hiruta, Y., Merkx, M., & Citterio, D. (2018) · Angewandte Chemie · doi:10.1002/ange.201808070 · Cited by 20
Augustin, D., Lambert, B. C., Robinson, M. J., Wang, K., & Gavaghan, D. J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1270443 · Cited by 17
Petrić, Z., Gonçalves, J., & Paixão, P. J. P. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091766 · Cited by 18
Wang, N., Zheng, L., Li, M., Hou, X., Zhang, B., Chen, J., Su, L., & Chen, L. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.02.009 · Cited by 16
Li, C., Shoji, S., & BEEBE, J. S. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13641 · Cited by 16
Haraya, K., & Tachibana, T. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01023-z · Cited by 14
Pharmacokinetic and Pharmacodynamic Modeling of Antibody-Drug Conjugates
Glassman, P. M. (2025) · Cancers · doi:10.3390/cancers18010005 · Cited by 13
Rudd, S. E., Noor, A., Morgan, K. A., & Donnelly, P. S. (2024) · Accounts of Chemical Research · doi:10.1021/acs.accounts.4c00092 · Cited by 12
A compartment model for subcutaneous injection of monoclonal antibodies
Zhong, X., Liu, Y., & Ardekani, A. M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123687 · Cited by 11
Bei, R., Thomas, J. W., Kapur, S., Woldeyes, M. A., Rauk, A. P., Robarge, J., Feng, J., & Oucherif, K. A. (2024) · mAbs · doi:10.1080/19420862.2024.2352887 · Cited by 12
Nakae, K., Masui, S., Yonezawa, A., Hashimoto, M., Watanabe, R., Murata, K., Murakami, K., Tanaka, M., Ito, H., Yokoyama, K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258601 · Cited by 11
Impact of altered endogenous IgG on unspecific mAb clearance
Fuhrmann, S., Kloft, C., & Huisinga, W. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9524-2 · Cited by 10
Masui, S., Yonezawa, A., Momo, K., Nakagawa, S., Itohara, K., Imai, S., Nakagawa, T., & Matsubara, K. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00906 · Cited by 9
Lim, A., Sharma, P. K., Stepanov, O., & Reddy, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051552 · Cited by 9
Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment
Berkhout, L. C., I'Ami, M. J., Kruithof, S., Vogelzang, E. H., Hooijberg, F., Hart, M. H. L., Bentlage, A. E. H., Thomas, D., Vermeire, S., Vidarsson, G., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16269 · Cited by 8
Ait‐Oudhia, S., Jaworowicz, D. J., Hu, Z., Bihorel, S., Hu, S., Budda, B., Mistry, B., Pena, J. D. O., Wenning, L. A., & Gheyas, F. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13166 · Cited by 7
Zhang, J., Wan, W., Miao, L., Wu, J. H., Dong, J., Shen, Y., Xiong, C., Li, C. R., Xue, Y., Cao, G., et al. (2020) · Rheumatology and Therapy · doi:10.1007/s40744-020-00193-9 · Cited by 7
Mennella, A., & Frasca, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199616 · Cited by 6
Does one model fit all mAbs? An evaluation of population pharmacokinetic models
van den Berg, S. P. H., Adolfsen, P. E. A., Dorlo, T. P. C., & Rispens, T. (2025) · mAbs · doi:10.1080/19420862.2025.2512217 · Cited by 5
Alez-Martin, L., Hirschler, E., Houzé, P., Potier, N., Mignet, N., Leize‐Wagner, E., François, Y., & Gahoual, R. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118385 · Cited by 4
Masuda, T., Funakoshi, T., Horimatsu, T., Yamamoto, S., Matsubara, T., Masui, S., Nakagawa, S., Ikemi, Y., Yanagita, M., Muto, M., et al. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04659-3 · Cited by 4
Management of anti-drug antibodies against TNF-inhibitors in sarcoidosis patients
Otten, B., Weinberg, D., Gregoski, M. J., & James, W. E. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108301 · Cited by 4
Shemesh, C. S., Wang, Y., An, A., Ding, H., Chan, P., Liu, Q., Chen, Y.-W., Wu, B., Wu, Q., & Wang, X. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04650-y · Cited by 4
Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria
ter Avest, M., Langemeijer, S. M. C., van den Heuvel, L. P., Baas, L. M., van de Kar, N. C. A. J., & ter Heine, R. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01536-x · Cited by 3
Weng, M., Yao, C., Lin, W., Lai, S.-K., Tung, C., Wang, C., Wong, J., Chen, P., & Wei, S.-C. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i41.111745 · Cited by 3
Wu, M., Huang, X., Chen, M., & Zhang⋆, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1353067 · Cited by 3
Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial
Derbalah, A., Abdulla, T., Mendes, M. D. S., Wu, Q., Stader, F., Jamei, M., Gardner, I. B., & Sepp, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050604 · Cited by 3
Fluctuations in Pharmacokinetics Profiles of Monoclonal Antibodies
Grabowski, T., Reijers, J. A. A., Burmańczuk, A., & Chełmońska‐Soyta, A. (2019) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-019-00548-w · Cited by 3
Yuan, H., & Silberstein, S. D. (2021) · Headache · doi:10.1007/978-3-030-69032-8_8 · Cited by 3
Pharmacokinetic modeling to optimize development and therapeutic potential of mAb-based therapies
Fan, X., Chen, C., Zhang, L., Cao, K., & Yan, X. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115850 · Cited by 2
Yan, D., Niu, S., Hu, D., Dong, W., Sun, Y., Wang, Q., Wang, S., Gu, Q., Liu, G., Wang, J., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2178894 · Cited by 2
Boisteau, É., François, É., Aparicio, T., Malicot, K. L., Boulahssass, R., Lecomte, T., Laurent‐Puig, P., Guiu, B., Paillaud, É., Galais, M., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.03.001 · Cited by 2
Variabilité pharmacocinétique des anticorps thérapeutiques
Ternant, D., & Chhun, S. (2019) · médecine/sciences · doi:10.1051/medsci/2019210 · Cited by 2
Looking backward to move forward: a chemist’s perspective on the future of radiopharmaceuticals
Rudd, S. E. (2025) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-025-02130-z · Cited by 1
Valk, A. M., van Strien, J., Derksen, N. I. L., Kos, D., Teixell, J. C., Janssen, J., Loeff, F. C., Dijk, L., Leeuw, M., Smith, C. H., et al. (2026) · BioDrugs · doi:10.1007/s40259-026-00792-y · Cited by 1
Suivi thérapeutique pharmacologique à la 4 e journée de pharmacologie des anti-tumoraux
Allard, M., Rousseau, B., Cardoso, E., Bellesœur, A., & Blanchet, B. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.06.006 · Cited by 1
Jiang, D., Parshad, S., Zhan, L. J., Sim, H., Siu, L. L., Liu, G., Shapiro, J. D., Price, T. J., Jonker, D. J., Karapetis, C. S., et al. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.08.006 · Cited by 1
Grempler, R., Ahlberg, J., Germovsek, E., Gupta, P., Li, H., Pilvankar, M., Sharma, A., Stopfer, P., & Hansel, S. B. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02710-y · Cited by 1
Pharmacokinetics of monoclonal antibodies locally-applied into the middle ear of guinea pigs
Kita, T., Yabe, Y., Maruyama, Y., Tachida, Y., Furuta, Y., Yamamura, N., Furuta, I., Yamahara, K., Ishikawa, M., Omori, K., et al. (2024) · Hearing Research · doi:10.1016/j.heares.2024.108950 · Cited by 1
Masuda, T., Funakoshi, T., Horimatsu, T., Masui, S., Hira, D., Inoue, M., Yajima, K., Nakagawa, S., Ikemi, Y., Hamanishi, J., et al. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04769-6 · Cited by 1
Chetty, M. (2018) · International Journal of Pharmacokinetics · doi:10.4155/ipk-2018-0002 · Cited by 1
Self-citationPhysiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Children
Malik, P. R. V. (2021) · UWSpace (University of Waterloo)
Innovative drug monitoring of factor VIII and emicizumab in haemophilia A
Donners, A. A. M. T. (2023) · doi:10.33540/1772
Detection of antibodies to infliximab in routine care: a 4-year French retrospective study
Bertin, D., Aghzadi, J., Balandraud, N., Roman, C., Serrero, M., & Desplat‐Jégo, S. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae122
OMG-RL: Offline Model-based Guided Reward Learning for heparin treatment
Lim, Y., & Lee, S. (2025) · Biomedical Engineering Advances · doi:10.1016/j.bea.2025.100198
Tachkov, K., Rumano, M., Bluett, J., Bogavac‐Stanojević, N., Dreesen, E., İtik, M., Kararigas, G., Kawalec, P., dos Santos, M. P. M., Skrede, S., et al. (2026) · Clinical and Translational Science · doi:10.1111/cts.70643
Metadata
- Authors
- Gill, K. L., Machavaram, K. K., Rose, R. H., & Chetty, M.
- Affiliations
- Simcyp (United Kingdom) (GB)
- Corresponding author
- Chetty, Manoranjenni
- Venue
- Clinical Pharmacokinetics
- Published
- 2016-01-27
- Volume
- 55
- Issue
- 7
- Pages
- 789-805
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W2296252503
- Cited by
- 82
- References
- 210
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 9 · 2023: 11 · 2022: 11 · 2021: 7 · 2020: 5 · 2019: 6 · 2018: 10 · 2017: 7 · 2016: 1
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- monoclonal antibodies, interindividual variability, pharmacokinetics, covariates, genetic polymorphism, population pharmacokinetic model, physiologically based pharmacokinetic modeling, dosing regimen, disease status, immune status, concomitant medications, comorbidities
- MeSH terms
- Age Factors, Antibodies, Monoclonal, Body Weights and Measures, Dose-Response Relationship, Drug, Drug Interactions, Ethnicity, Humans, Lymphatic System, Models, Biological, Polymorphism, Genetic, Receptors, Fc, Severity of Illness Index, Sex Factors, Histocompatibility Antigens Class I, Comorbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
